BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20620720)

  • 1. Cardiovascular events during differing hypertension therapies in patients with diabetes.
    Weber MA; Bakris GL; Jamerson K; Weir M; Kjeldsen SE; Devereux RB; Velazquez EJ; Dahlöf B; Kelly RY; Hua TA; Hester A; Pitt B;
    J Am Coll Cardiol; 2010 Jun; 56(1):77-85. PubMed ID: 20620720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
    Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
    Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
    Jamerson K; Weber MA; Bakris GL; Dahlöf B; Pitt B; Shi V; Hester A; Gupte J; Gatlin M; Velazquez EJ;
    N Engl J Med; 2008 Dec; 359(23):2417-28. PubMed ID: 19052124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
    Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA
    J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease.
    Bakris G; Briasoulis A; Dahlof B; Jamerson K; Weber MA; Kelly RY; Hester A; Hua T; Zappe D; Pitt B;
    Am J Cardiol; 2013 Jul; 112(2):255-9. PubMed ID: 23582626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
    Weber MA; Jamerson K; Bakris GL; Weir MR; Zappe D; Zhang Y; Dahlof B; Velazquez EJ; Pitt B
    Lancet; 2013 Feb; 381(9866):537-45. PubMed ID: 23219284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
    Bakris G; Hester A; Weber M; Dahlof B; Pitt B; Velasquez E; Staikos-Byrne L; Shi V; Jamerson K;
    J Cardiometab Syndr; 2008; 3(4):229-33. PubMed ID: 19040592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study.
    Kjeldsen SE; Jamerson KA; Bakris GL; Pitt B; Dahlöf B; Velazquez EJ; Hua TA; Kelly RY; Zappe D; Hester A; Tuomilehto J; Ostergren J; Ibsen H; Weber M;
    Blood Press; 2012 Apr; 21(2):82-7. PubMed ID: 21830844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
    Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
    Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
    Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 24-hour ambulatory blood pressure in the ACCOMPLISH trial.
    Jamerson KA; Bakris GL; Weber MA
    N Engl J Med; 2010 Jul; 363(1):98. PubMed ID: 20592305
    [No Abstract]   [Full Text] [Related]  

  • 13. The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a comparison of first-line combination therapies.
    Weder AB
    Expert Opin Pharmacother; 2005 Feb; 6(2):275-81. PubMed ID: 15757423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes.
    Roca-Cusachs A; Schmieder RE; Triposkiadis F; Wenzel RR; Laurent S; Kohlmann O; Fogari R;
    J Hypertens; 2008 Apr; 26(4):813-8. PubMed ID: 18327093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control.
    Jamerson KA; Devereux R; Bakris GL; Dahlöf B; Pitt B; Velazquez EJ; Weir M; Kelly RY; Hua TA; Hester A; Weber MA
    Hypertension; 2011 Feb; 57(2):174-9. PubMed ID: 21189401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study].
    Fan CM; Yan LR; Tao YK; Wang L; Li YQ; Gao MM; Wang YN; Li CX; Wang XW; Lu XL; Pang HM; Li YS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jan; 39(1):57-60. PubMed ID: 21418799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial.
    Skoglund PH; Svensson P; Asp J; Dahlöf B; Kjeldsen SE; Jamerson KA; Weber MA; Jia Y; Zappe DH; Östergren J;
    J Clin Hypertens (Greenwich); 2015 Feb; 17(2):141-6. PubMed ID: 25529596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
    Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension.
    Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber MA; Jamerson KA
    Am J Hypertens; 2021 May; 34(5):531-539. PubMed ID: 33216879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.